Bryan Gilburg - China

“The TFDA is planning to cut the pre-screening time from 30 days to 1 and cut application review times by up to 40%.”

Noi Suwannabot

General Manager, Asia Actual Thailand

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sign Up For Our Newsletter to Stay Informed

Sign Up

Thai FDA to Decrease Registration Application Processing Times

Published on: January 25th, 2024

On January 15th and 16th the Thai FDA hosted a seminar for public discussion and training of the full CDST application, which was attended by Asia Actual Thailand personnel. At the event, the Thai FDA announced its intention to decrease the application pre-screening time from 30 days to 1 working day. Likewise, the target review time for risk class 2-4 medical device application review times are being reduced from 200 days to 120 calendar days without an Expert Review; and from 250 days to 150 calendar days for applications subject to Expert Review. These changes are expected to be fully implemented in Q1 of this year.

Advertising Review Time Update

Another welcome change is that advertising approval application for certain risk class 1 medical device will be subject to automatic approval. More information on this announcement can be found here.

The advertising review process in Thailand poses challenges and consumes time, particularly for advertisers targeting direct-to-consumer markets. The TFDA scrutinizes all advertisements to verify the accuracy and substantiation of the claims made. Advertisements targeting Healthcare Professionals (HCPs) are exempt from mandatory review but must be submitted through an online portal before being placed on the market.

Come Grow with Us

Please contact Asia Actual with any questions or requests for support in Thailand. We have offices staffed by experienced, bilingual regulatory and commercial professionals in the major capital cities of Asia. Our mission is to provide a stable, reliable local platform so that our clients can grow their sales in challenging Asian markets.

.

Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.